Taysha Gene Therapies Balance Sheet
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Taysha Gene Therapies financial position
At the end of fiscal 2025, Taysha Gene Therapies reported total assets of $343.3 million, up 114.1% from a year earlier against total liabilities of $96.4 million. Shareholders' equity stood at $246.9 million, or 71.9% of assets. The company held $319.8 million in cash and equivalents against $50.1 million of debt, a net cash position of $269.7 million.
The current ratio (current assets divided by current liabilities) was 12.23, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.20.
Summary generated from market data by MetaCap's automated system. Methodology
Taysha Gene Therapies balance sheet (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 319.77M | 139.04M | 143.94M | 87.88M | 149.10M | 251.25M |
| Total Current Assets | 324.65M | 142.13M | 149.87M | 96.42M | 159.60M | 257.88M |
| Property, Plant & Equipment | 6.74M | 7.49M | 10.83M | 14.96M | 50.61M | 287.00K |
| Total Assets | 343.32M | 160.36M | 172.73M | 126.28M | 213.96M | 258.88M |
| Accounts Payable | 6.28M | 3.59M | 6.37M | 10.95M | 21.76M | 1.99M |
| Total Current Liabilities | 26.55M | 26.23M | 36.76M | 62.79M | 51.75M | 7.13M |
| Long-Term Debt | 50.11M | 43.94M | 40.51M | 37.97M | 37.19M | — |
| Total Liabilities | 96.38M | 88.84M | 97.79M | 125.33M | 118.57M | 7.58M |
| Shareholders' Equity | 246.94M | 71.53M | 74.94M | 949.00K | 95.38M | 251.30M |
| Retained Earnings | -711.30M | -602.30M | -513.01M | -401.44M | -235.65M | -61.13M |
| Total Debt | 50.11M | 43.94M | 40.51M | 37.97M | 37.19M | — |
| Net Cash (Debt) | 269.66M | 95.09M | 103.43M | 49.91M | 111.91M | 251.25M |
| Shares Outstanding | 285.05M | 204.94M | 186.96M | 63.21M | 38.47M | 37.76M |
This table shows 6 annual periods of Taysha Gene Therapies's balance sheet, from FY 2025 back to FY 2020, across 13 line items including cash & equivalents, total current assets, property, plant & equipment. Values in USD; B = billions, M = millions. Fiscal periods follow TSHA's reporting calendar. What is a balance sheet?